VOR BIOPHARMA INC
VORNASDAQTrading Snapshot
- Day Range
- $20.66 – $21.59
- 52-Week Range
- $6.50 – $26.80
- Volume (shares)
- 965,843
- Avg Volume (shares)
- —
- Shares Outstanding
- 54.2M
- Next Earnings
- 2026-11-11
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- 0.1
- P/S Ratio
- 0.0x
- EPS (TTM)
- $11.56
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +187.4%
VOR BIOPHARMA INC
VOR
StockOtter · stockotter.spaceAbout VOR BIOPHARMA INC
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Vor Bio says its experimental drug slowed loss of kidney function in late-stage study
Vor Bio says its experimental drug slowed loss of kidney function in late-stage study
Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy
Annualized eGFR slope of -0.6 vs. -5.7 mL/min/1.73 m²/year for placebo, a 5.1 mL/min/1.73 m²/year treatment difference (p
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on October 1, 2026, the Compensation Commit
Vor Biopharma (NASDAQ:VOR) Shares Up 5.3% – What’s Next?
Vor Biopharma Inc. (NASDAQ: VOR - Get Free Report)'s stock price was up 5.3% on Wednesday. The stock traded as high as $19.30 and last traded at $19.3050. Approximately 100,789 shares changed hands during trading, a decl
Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
More than 94% of participants achieved a ≥5-point MG-ADL improvement at Week 48 42% of telitacicept-treated participants achieved minimal symptom expression (MSE) at any time over 48 weeks, increasing from 23.7% over the
Vor Biopharma: A Funded Replication Story With Franchise Potential
Vor Biopharma is advancing telitacicept globally, leveraging strong Chinese clinical evidence and a robust $514.5M liquidity position. VOR's global Phase 3 trials in myasthenia gravis and Sjögren's are fully enrolled or